At the end of IDIX’s Citi webcast, CFO Ron Renaud mentioned in passing that the phase-2b trials of IDX899 vs Sustiva (first-line setting) and IDX899 vs Intelence (second-line setting) are expected to start in late 2010 rather than the current quarte, as previously guided (#msg-47558107). Renaud also said the IDX899 + GSK1349572 phase-2b “nuke-sparing” trial is expected to start in early 2011 rather than late 2010, as previously guided.
Thanks for the info Dew. Not something one wants to hear, but I tend to view 899 as one of the least consequential drugs in IDIX's drug portfolio given the possibility/probability? of GILD moving to their own proprietary HIV cocktail. If things continue to move forward on the HCV front for IDIX, I think we're in quite good shape even after the nice run-up of late.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.